

# Proficiency Test Final Report AQA 23-22 Cocaine

June 2024

© Commonwealth of Australia 2024.

Unless otherwise noted, the Commonwealth owns the copyright (and any other intellectual property rights, if any) in this publication.

All material in this publication is provided under a Creative Commons Attribution 4.0 International Licence (CC BY 4.0), with the exception of:

- the Commonwealth Coat of Arms;
- the logo of the Department of Industry, Science and Resources;
- photographs of our staff and premises; and
- content supplied by third parties.

Creative Commons Attribution 4.0 International Licence is a standard form licence agreement that allows you to copy, distribute, transmit and adapt this publication provided you attribute the work. A summary of the licence terms is available at:

<u>creativecommons.org/licenses/by/4.0/</u>. Further details are available on the Creative Commons website, at: creativecommons.org/licenses/by/4.0/legalcode.

You may not copy, distribute, transmit or adapt any material in this publication in any way that suggests that this department or the Commonwealth endorses you or any of your services or products.

### Attribution

Material contained in this publication is to be attributed to this department as:

© Commonwealth of Australia, Department of Industry, Science and Resources, Proficiency Test Final Report AQA 23-22 Cocaine, 2024.

### Third party copyright

Wherever a third party holds copyright in material contained in this publication, the copyright remains with that party. Their permission may be required to use the material.

This department has made all reasonable efforts to:

- clearly label material where the copyright is owned by a third party;
- ensure that the copyright owner has consented to this material being contained in this publication.

### **Using the Commonwealth Coat of Arms**

The terms of use for the Coat of Arms are available on the Department of Prime Minister and Cabinet's website, at <a href="https://www.pmc.gov.au/resource-centre/government/commonwealth-coat-arms-information-and-guidelines">www.pmc.gov.au/resource-centre/government/commonwealth-coat-arms-information-and-guidelines</a>

### **ACKNOWLEDGMENTS**

This study was conducted by the National Measurement Institute (NMI). Support funding was provided by the Australian Government Department of Industry, Science and Resources.

I would like to thank the management and staff of the participating laboratories for supporting the study. It is only through widespread participation that we can provide an effective service to laboratories.

The assistance of the following NMI staff members in the planning, conduct and reporting of the study is acknowledged.

Jenny Xu

Lesley Johnston

Raluca Iavetz

Manager, Chemical Reference Values

105 Delhi Rd, North Ryde, NSW 2113, Australia

Phone: +61 2 9449 0178

Email: raluca.iavetz@measurement.gov.au



Accredited for compliance with ISO/IEC 17043

### **TABLE OF CONTENTS**

SI	UMM	IARY	1
1	١N	NTRODUCTION	2
	1.1	NMI Proficiency Testing Program	2
	1.2	Study Aims	2
	1.3	Study Conduct	2
2	S	TUDY INFORMATION	3
	2.1	Study Timetable	3
	2.2	Participation and Laboratory Code	3
		Test Material Specification	3
	2.4	Test Sample Homogeneity and Stability	3
		Sample Dispatch	4
	2.6	Instructions to Participants	4
	2.7	Interim Report and Preliminary Report	4
3	P	ARTICIPANT LABORATORY INFORMATION	5
	3.1	Test Methods Reported by Participants	5
		Details of Participant Calibration Standard	6
	3.3	Reported Basis of Participants' Measurement Uncertainty Estimates	7
	3.4	Participant Comments	11
4	Р	RESENTATION OF RESULTS AND STATISTICAL ANALYSIS	12
	4.1	Results Summary	12
	4.2	Assigned Value	12
	4.3	Robust Average and Robust Between-Laboratory Coefficient of Variation	12
	4.4	Performance Coefficient of Variation	12
	4.5	Target Standard Deviation for Proficiency Assessment	13
	4.6	z-Score	13
	4.7	E <sub>n</sub> -Score	13
	4.8	Traceability and Measurement Uncertainty	13
5	T.	ABLES AND FIGURES	14
6	D	ISCUSSION OF RESULTS	21
	6.1	Assigned Value	21
	6.2	Measurement Uncertainty Reported by Participants	21
	6.3	z-Score	21
	6.4	E <sub>n</sub> -Score	22
	6.5	Identification of Cutting Agent	23
	6.6	Participants' Analytical Methods	23
	6.7	Comparison of Results and Date of Analysis	26
	6.8	Comparison with Previous Cocaine PT Studies	27
7	R	EFERENCES	30
		NDIX 1 ROBUST AVERAGE AND ASSOCIATED UNCERTAINTY, z-SCORE	AND
E		ORE CALCULATIONS	31
		Robust Average and Associated Uncertainty	31
		2 z-Score and E <sub>n</sub> -Score Calculations	31
Αl	PPE	NDIX 2 ACRONYMS AND ABBREVIATIONS	32

### **SUMMARY**

AQA 23-22 Cocaine commenced in September 2023. Sample sets, each containing three samples of cocaine hydrochloride, were sent to twenty-nine laboratories, with one laboratory requesting two sets of samples to be analysed by different analysts. All participants returned results.

Samples were prepared at the National Measurement Institute (NMI) laboratory in Sydney using seizures of cocaine hydrochloride supplied by the Australian Federal Police.

The assigned values were the robust averages of participants' results.

**Traceability**: The consensus of participants' results is not traceable to any external reference, so although expressed in SI units, metrological traceability has not been established.

The outcomes of the study were assessed against the aims as follows:

• Assess the proficiency of laboratories measuring cocaine in samples typical of a routine seizure.

Laboratory performance was assessed by *z*-score and  $E_n$ -score.

Of 88 z-scores, 70 (80%) returned  $|z| \le 2.0$ , indicating an acceptable performance.

Of 88  $E_n$ -scores, 75 (85%) returned  $|E_n| \le 1.0$ , indicating agreement of the participant's result with the assigned value within their respective expanded uncertainties.

Laboratories 3, 4, 6, 8, 10, 12, 13, 21, 22, 24, 26 and 27 returned acceptable *z*-scores and  $E_n$ -scores for all three samples.

• Develop a practical application of traceability and measurement uncertainty, and provide participants with information that will assist uncertainty estimates.

Of 88 numeric results, 85 (97%) were reported with an associated expanded measurement uncertainty. The magnitude of reported uncertainties was within 0.7% to 67% relative.

The metrological traceability of the assigned values has not been established as they were the consensus of participants' results.

• Test the ability of participants to identify cutting agents commonly found in controlled drug preparation.

Sample S1 was cut with paracetamol, Sample S3 was cut with glucose, and no cutting agents were added to Sample S2.

Twenty-six participants (87%) reported on the identity of the cutting agent(s) in at least one sample.

Laboratories 2, 4, 6, 8, 13, 16, 23, 24, 25, 27 and 29 correctly identified all cutting agents in the samples.

• Produce materials that can be used in method validation and as control samples.

The test samples of this study are homogeneous and are well characterised. Samples are available for purchase from NMI and can be used for quality control and method validation purposes.

### 1 INTRODUCTION

### 1.1 NMI Proficiency Testing Program

The National Measurement Institute (NMI) is responsible for Australia's national measurement infrastructure, providing a range of services including a chemical proficiency testing program.

Proficiency testing (PT) is the 'evaluation of participant performance against pre-established criteria by means of interlaboratory comparisons'. NMI PT studies target chemical testing in areas of high public significance such as trade, environment, law enforcement and food safety. NMI offers studies in:

- pesticide residues in fruit, vegetables and herbs, soil and water;
- petroleum hydrocarbons in soil and water;
- per- and polyfluoroalkyl substances in water, soil, biosolid, food and biota;
- inorganic analytes in soil, water, filters, food and pharmaceuticals;
- controlled drug assay, drugs in wipes and clandestine laboratory; and
- allergens in food.

### 1.2 Study Aims

The aims of the study were to:

- assess the proficiency of laboratories measuring cocaine in samples typical of a routine seizure;
- develop a practical application of traceability and measurement uncertainty, and provide participants with information that will assist uncertainty estimates;
- test the ability of participants to identify cutting agents commonly found in controlled drug preparation; and
- produce materials that can be used in method validation and as control samples.

The choice of test method was left to the participating laboratories.

### 1.3 Study Conduct

The conduct of NMI proficiency tests is described in the NMI Study Protocol for Proficiency Testing.<sup>2</sup> The statistical methods used are described in the NMI Chemical Proficiency Testing Statistical Manual.<sup>3</sup> These documents have been prepared with reference to ISO/IEC 17043 and The International Harmonized Protocol for Proficiency Testing of Analytical Chemistry Laboratories.<sup>1,4</sup>

NMI is accredited by the National Association of Testing Authorities, Australia (NATA) to ISO/IEC 17043 as a provider of proficiency testing schemes.<sup>1</sup> This controlled drug PT study is within the scope of NMI's accreditation.

### 2 STUDY INFORMATION

### 2.1 Study Timetable

The timetable of the study was:

 Invitations sent
 18/09/2023

 Samples sent
 11/12/2023

 Results due
 10/05/2024

 Interim report
 16/05/2024

 Preliminary report
 20/05/2024

There were substantial delivery delays to some participants, and so the project timeline was extended significantly.

### 2.2 Participation and Laboratory Code

Twenty-nine laboratories enrolled to participate in this study. One laboratory requested two sets of test samples to be analysed by different analysts. Each participant was randomly assigned a confidential laboratory code for this study. All participants returned results.

### 2.3 Test Material Specification

Three test samples were prepared in October 2023. The starting material was two batches of cocaine hydrochloride samples supplied by the Australian Federal Police. One batch was used to prepare Sample S1, and the other batch was used to prepare Samples S2 and S3.

4-Acetamidophenol (paracetamol) purchased from Sigma Aldrich and glucose purchased from a local pharmacy were used as cutting agents. Sample S1 was cut with paracetamol, Sample S3 was cut with glucose, and no cutting agents were added to Sample S2.

The cocaine was ground and sieved through a 180 µm sieve. The cutting agents were processed similarly. Test samples were then prepared by mixing a known mass of sieved drug material with a known mass of sieved cutting agent in a tumbler overnight. Portions of 150 mg of each of the test samples were then weighed out into labelled glass vials.

There are no preparation values provided for Samples S2 and S3 as the mass fraction of the cocaine hydrochloride used for these samples was not accurately known.

Sample S1 was prepared to contain approximately 60% cocaine base (m/m).

### 2.4 Test Sample Homogeneity and Stability

The preparation of homogeneous test samples is an important part of a PT study. Given the small (<150 mg) test portions normally used for controlled substances analysis, the particle size must be sufficiently small and uniformly distributed to ensure minimal influence on analytical precision.

No homogeneity testing was conducted in this PT study. Samples were prepared using the same procedure as previous controlled drug PT studies, which has been demonstrated to produce sufficiently homogeneous samples. Results returned by the participants gave no reason to question the homogeneity of the test samples.

To assess the stability of the samples, results returned by participants were compared to the dates of analysis (Section 6.7). The results gave no reason to question the stability of the test samples.

### 2.5 Sample Dispatch

A set of three test samples, with each sample containing approximately 150 mg of test material, was dispatched to each participant in December 2023. The following items were also packaged with the samples:

- a covering letter with instructions for participants; and
- a form for participants to confirm the receipt of the test samples.

An Excel spreadsheet for the electronic reporting of results was emailed to participants.

### 2.6 Instructions to Participants

Participants were instructed as follows:

- Analyse each sample for amount of drug by your normal test method. It is recommended to thoroughly mix the content of each vial before taking a test portion for analysis.
- For each sample report % m/m cocaine as base. Report this figure as if reporting to a client.
- For each result report an estimate of the expanded uncertainty as % m/m cocaine as base.
- Report the identity of cutting agent(s) in all three samples if this is within your normal scope of analysis.
- A result spreadsheet has been emailed to you. Please complete this spreadsheet and return by email to jenny.xu@measurement.gov.au.
- Give brief details in the results sheet of your:
  - Basis of uncertainty estimate (e.g. uncertainty budget method, repeatability precision).
  - o Analytical method (e.g. sample treatment, instrument type, calibration method).
  - o Reference standard (e.g. source, purity)
- Results are to be returned by 12 February 2024.

There were significant delivery delays to some international participants due to delays with receiving export permits, and so the results due date was extended to 10 May 2024.

### 2.7 Interim Report and Preliminary Report

An Interim Report was emailed to all participants on 16 May 2024.

A Preliminary Report was emailed to all participants on 20 May 2024. This report included a summary of the results reported by participants, assigned values, performance coefficient of variations (PCVs), z-scores and  $E_n$ -scores for each analyte in this study. No data from the Preliminary Report has been changed in the present Final Report.

### 3 PARTICIPANT LABORATORY INFORMATION

### 3.1 Test Methods Reported by Participants

Participants were requested to provide information about their test methods. Responses are presented in Table 1. Some responses may be modified so that the participant cannot be identified.

Table 1 Summary of Participants' Test Methods

Lab. Code	Extraction Solvent	Internal Standard	Calib. Points	Technique	Detector	Column
1	Methanol	Diazepam	6	GC	FID	J&W 128-5512
2	Deuterium oxide	Maleic acid		NMR	Bruker AVIII 400 with BBO Prodigy cryoprobe	N/A
3	Acetonitrile/Deionised water (25:75) + 0.1% (by volume) Trifluoroacetic Acid	N/A	3	HPLC	DAD	OD52 Interpack column (25cm x 5.4mm)
4	acetonitrile/water (80/20)	external standard	3	HPLC	DAD	C8
5	Ethanol	Propyl Paraben	7	UPLC	DAD	BEH Shield RP18
6	CDC13	TMSB		QNMR		
7	Acetonitrile/Methanol	Pholcodine 1mg/ml	3	UPLC	PDA	ACQUITY C-18
8	Ethanol	Triphenylacetophenone (TPAP)	3	GC	FID	HP1 MS
9	Methanol		4	HPLC	DAD	ECLIPSE XDB-C18
10	Acetonitrile	NA	4	HPLC	UV/Vis	PROTECOL C8 H 5UM 150X4.6MM
11	Methanol		7	HPLC	DAD	ZORBAX XDB-C18 (4.6x150 mm, 5μm)
12	Methanol	Tetracosane	4	GC	FID	HP5 30m x 0.32 mm x 0.25 μm
13	Ethanol	Tribenzylamine	6	GC	FID	HP5
14	Acetonitrile:Water (75:25)	Dibutylphthalate	3	UPLC	PDA	Acquity UPLC BEH C18 1.7µm (2.1x100mm)

La	b. Code	Extraction Solvent	Internal Standard	Calib. Points	Technique	Detector	Column
15		H2O/Acetonitrile (60/40)		5	UPLC	DAD	KROMASIL
	16	Methanol	Methadone	4	GC	FID	RXI-5MS
	17	HPLC Methanol	Vanillin	1	UPLC	DAD	Agilent Lichrospher 60 RP-select B
	18	Methanol	none	5	HPLC	DAD	Kinetex 2.6 μ XB-C18
	19	ACN/MeOH/H2O	Analog of cocaine	7	UPLC	MS/MS	C-18 Column
	20	Chloroform	Octacosane	5	GC	MS	Zebron ZB-5MSplus
	21	Ethanol	Tetracosane	3	GC	FID	BPX-5
	22	Methanol	- External calibration	3	GC	FID	CP-sil5CB
	23	Methanol	nil	7	HPLC	PDA	Waters HPLC 1260 Phenomenex C8 Luna 3u Narrow Bore 100 mm
	24	Acetonitrile	Strychnine	6	GC	FID	Phenyl
25	S1, S3	Chloroform	benzopinacolone	1	GC	FID	HP-1
25	S2	Mobile phase	none	4	HPLC	PDA	S2: C18 ubondpak
	26	Ethanol	Tetracosane	6	GC	FID	HP5
	27	acetonitrile/water (80/20)	none	3	HPLC	DAD	C8
28		acetonitrile/water	none	5	HPLC	DAD	Kromasil
	29	water/acetonitrile/2.5M sulfuric acid 90:10:1	None	3	HPLC	Diode Array	Shimpack XR-ODS
	30	HPLC Methanol	Vanillin	1	UPLC	DAD	Agilent LiChrospher 60 RP-select B

### 3.2 Details of Participant Calibration Standard

Participants were requested to provide information about their calibration standard. Responses are presented in Table 2. Some responses may be modified so that the participant cannot be identified.

Table 2 Participant Calibration Standard

Lab. Code	Reference Standard	Purity (%)
1	Lipomed	99.3
2	Sigma Aldrich	$99.94 \pm 0.15$
3	TRC	98
4	EUROMEDEX	86.7
5	NMI	99.8
6	NMI	99.7
7	NMI	99.8
8	NMI	99.8
9		
10	Lipomed (cocaine HCl)	99.004
11	Lipomed	99.9
12	Chiron	99.5 +/- 1.5
13	Lipomed	99.199
14	NMI	99.8
15	Lipomed (EUROMEDEX)	99.5

Lab. Code	Reference Standard	Purity (%)
16	LGC	99.8
17	Lipomed	99.199 ± 0.006
18	Lipomed	>98.6
19	Unikem	100
20	lipomed	99.199
21	NMI	99.8
22	Duchefa	>99
23	NMI	99.8
24	NMI	99.8
25	MacFarlan Smith	99.6
26	Alcaliber	100.7
27	Lipomed	99.004
28	Lipomed	99
29	LGC (Mikromol)	99.9
30	Lipomed	$99.199 \pm 0.006$

### 3.3 Reported Basis of Participants' Measurement Uncertainty Estimates

Participants were requested to provide information about their basis of measurement uncertainty (MU). Responses are presented in Table 3. Some responses may be modified so that the participant cannot be identified.

Table 3 Reported Basis of Uncertainty Estimate

Lab.	Annual of Estimation Mil	Information Sources	s for MU Estimation*	Cuido Do cument for Estimating MII
Code	Approach to Estimating MU	Precision	Method Bias	Guide Document for Estimating MU
1	Estimating Measurement Uncertainty by black box with pair of values $k=2 \label{eq:k}$	Standard deviation from PT studies only		ISO/GUM ENAC G 09 or ISO 21748
2	Bottom Up (ISO/GUM, fish bone/cause and effect diagram) Coverage factor not reported	Control samples - CRM Duplicate analysis		
3	Standard deviation of replicate analyses multiplied by 2 or 3 Coverage factor not reported	Control samples - SS	Instrument calibration Masses and volumes Recoveries of SS	ISO/GUM
4	Top Down - reproducibility (standard deviation) from PT studies used directly Coverage factor not reported	Control samples - RM Duplicate analysis	Instrument calibration Laboratory bias from PT studies	Eurachem/CITAC Guide
5	Coverage factor not reported			
6	Top Down - precision and estimates of the method and laboratory bias $k = 2$ Control samples - check sample cocaine seizure Duplicate analysis		Standard purity	NMI Uncertainty Course
7	Top Down - precision and estimates of the method and laboratory bias Coverage factor not reported	Control samples - CRM Duplicate analysis	Instrument calibration Masses and volumes	NATA GAG Estimating and Reporting Measurement Uncertainty of Chemical Test Results
8	Bottom Up (ISO/GUM, fish bone/cause and effect diagram) $k=2$	Control samples - CRM Duplicate analysis	Instrument calibration Homogeneity of sample Masses and volumes Matrix effects Recoveries of SS Standard purity	Eurachem/CITAC Guide
9	Top Down - precision and estimates of the method and laboratory bias Coverage factor not reported	Control samples - RM	Recoveries of SS	Eurolab Technical Report No1/2007

Lab.	Annua de la Estimatina MII	Information Sources	for MU Estimation*	Cycide Decomment for Estimating MII	
Code	Approach to Estimating MU	Precision	Method Bias	Guide Document for Estimating MU	
10	Standard deviation of replicate analyses multiplied by 2 or 3 $k = 2$	Control samples - RM	Laboratory bias from PT studies		
11	VALIDATION DATA Coverage factor not reported	Control samples - CRM Duplicate analysis	Instrument calibration Masses and volumes Standard purity	Eurachem/CITAC Guide	
12	Top Down - precision and estimates of the method and laboratory bias $k = 1$ Control samples - authentic samples Duplicate analysis		Instrument calibration Matrix effects Laboratory bias from PT studies Recoveries of SS Standard purity	EA-04/16, EA guidelines on the expression of uncertainty in quantitative testing	
13	Top Down - precision and estimates of the method and laboratory bias Coverage factor not reported  Top Down - precision and estimates of Control samples - RM		Standard purity		
14	Top Down - precision and estimates of the method and laboratory bias $k = 2$ Duplicate analysis		Homogeneity of sample Standard purity	Eurachem/CITAC Guide	
15	Top Down - precision and estimates of the method and laboratory bias $k = 2$ Control samples - R		Laboratory bias from PT studies	ISO/GUM	
16	Standard deviation of replicate analyses multiplied by 2 or 3 Duplicate $k = 2$		Masses and volumes	ISO/GUM	
17	$ \begin{array}{c} \text{Top Down - precision and estimates of} \\ \text{the method and laboratory bias} \\ \text{$k=2$} \end{array} \qquad \begin{array}{c} \text{Control samples - SS} \\ \text{Duplicate analysis} \end{array} $		Laboratory bias from PT studies Recoveries of SS	Eurachem/CITAC Guide	
18	Top Down - precision and estimates of the method and laboratory bias $k = 3$	Control samples Duplicate analysis	Instrument calibration Masses and volumes Recoveries of SS	Eurachem/CITAC Guide	

Lab.	Annual to Estimating MII	Information Sources	for MU Estimation*	Guide Document for Estimating MU	
Code	Approach to Estimating MU	Precision	Method Bias	Guide Document for Estimating MO	
19	Top Down - precision and estimates of the method and laboratory bias $k=0.95 \label{eq:kappa}$	Control samples - RM		Eurachem/CITAC Guide ILAC-G17 and EA 4/16 (2003)	
20	Top Down - precision and estimates of the method and laboratory bias $k=2 \label{eq:kappa}$	Control samples - CRM Duplicate analysis	Laboratory bias from PT studies	ISO/GUM	
21	Uncertainty Budget Method Control samples - RM Duplicate analysis		Instrument calibration Masses and volumes Standard purity	Internal SOP Document	
22	Top Down - precision and estimates of the method and laboratory bias Coverage factor not reported  Control samples - SS Duplicate analysis		Instrument calibration Recoveries of SS	ISO/GUM	
23	Top Down - precision and estimates of the method and laboratory bias Coverage factor not reported  Control samples - in-house control Duplicate analysis		Standard purity	ISO/GUM	
24	Top Down - precision and estimates of the method and laboratory bias $k=2 \label{eq:k} % \begin{array}{c} k=2 \\ \end{array}$	Control samples - CRM Duplicate analysis	Homogeneity of sample Masses and volumes Laboratory bias from PT studies	ISO/GUM	
25	validation $k=2$				
26	Top Down - precision and estimates of the method and laboratory bias $k=2 \label{eq:k} % \begin{array}{c} k=2 \\ \end{array}$	Control samples Duplicate analysis	Matrix effects Standard purity	ISO/GUM	
27	Top Down - precision and estimates of the method and laboratory bias $k=2$ Control samples		Laboratory bias from PT studies	NF V03-110	
28	Standard deviation of replicate analyses multiplied by 2 or 3 Coverage factor not reported	Control samples - RM		ISO/GUM	

Lab.	Approach to Estimating MII	Information Sources	Cuida Dagumant for Estimating MII	
Code	Approach to Estimating MU	Precision	Method Bias	Guide Document for Estimating MU
29	Standard deviation of replicate analyses multiplied by 2 or 3 $k = 3$	Control samples - CRM Duplicate analysis	Instrument calibration Standard purity	ISO/GUM
30	Top Down - precision and estimates of the method and laboratory bias $k=2 \label{eq:k}$	Control samples - SS Duplicate analysis	Laboratory bias from PT studies Recoveries of SS	Eurachem/CITAC Guide

<sup>\*</sup> CRM = Certified Reference Material, RM = Reference Material, SS = Spiked Samples

### 3.4 Participant Comments

The study coordinator welcomes comments or suggestions from participants that may improve future studies. Comments received in this study are presented in Table 4. Some responses may be modified so that the participant cannot be identified.

**Table 4 Participant Comments** 

Lab. Code	Participants' Comments	Study Co-ordinator's Response
2	Methodology: Simultaneous observation of analyte and IS peaks in 1H NMR spectrum acquired using QNMR conditions	
3	Methodology: Less than 20mg used as analysis carried out as per the laboratory procedure (approx 10mg to be sampled)	
8	Sample S3 may contain additional sugars in addition to glucose at a low level. Methodology: A small amount of dichloromethane is used to dissolve the TPAP.	
27	Is it possible to put a sample around 5% and another around 80% or more? Indicate the measurement wavelength used by other labs for HPLC. Allow indication of the form of cocaine identified as HCl or base for all 3 samples. For this test, we identified cocaine HCl in the 3 samples (S1, S2 and S3) by IR. Methodology: results at 230nm	We aim to select a range of purities to cater for the needs of different laboratories, and previous NMI Cocaine PT studies have included samples of similar levels as those suggested here. For this study, the assigned values ranged from 14.1 % base (m/m) to 80.9 % base (m/m).  We will take into consideration your other suggestions when preparing results sheets in future.
29	Uncertainty: MuM determined from multiple injections of reference material. 3x(Std Dev/mean)x100.	

### 4 PRESENTATION OF RESULTS AND STATISTICAL ANALYSIS

### 4.1 Results Summary

Participant results are listed in Tables 5 to 7 with the summary statistics: robust average, median, mean, number of numeric results (N), maximum (Max), minimum (Min), robust standard deviation (Robust SD) and robust coefficient of variation (Robust CV).

Bar charts of results and performance scores are presented in Figures 2 to 4. An example chart with interpretation guide is shown in Figure 1.




Figure 1 Guide to Presentation of Results

### 4.2 Assigned Value

The assigned value is defined as the 'value attributed to a particular property of a proficiency test item'. In this study, the property is the % cocaine base (m/m) in the test samples. The assigned values were the robust averages of participants' results, and the expanded uncertainties were estimated from the associated robust SDs (Appendix 1).

### 4.3 Robust Average and Robust Between-Laboratory Coefficient of Variation

The robust averages and associated expanded MUs, and robust CVs (a measure of the variability of participants' results) were calculated using the procedure described in ISO 13528.<sup>5</sup>

### 4.4 Performance Coefficient of Variation

The performance coefficient of variation (PCV) is a measure of the between-laboratory variation that in the judgement of the study coordinator would be expected from participants, given the levels of analytes present. The PCV is set by the study coordinator, and it is not the CV of participants' results. The PCV is based on the mass fraction of the analytes and experience from previous studies, and is also supported by mathematical models such as the Thompson-Horwitz equation. By setting a fixed and realistic value for the PCV, a participant's performance does not depend on other participants' performances, and can be compared from study to study.

### 4.5 Target Standard Deviation for Proficiency Assessment

The target standard deviation for proficiency assessment ( $\sigma$ ) is the product of the assigned value (X) and the PCV, as presented in Equation 1.

$$\sigma = X \times PCV$$

### 4.6 z-Score

For each participant result, a z-score is calculated according to Equation 2.

$$z = \frac{(\chi - X)}{\sigma}$$

Equation 2

where:

z is z-score

 $\chi$  is a participant's result

X is the assigned value

 $\sigma$  is the target standard deviation for proficiency assessment from Equation 1

For the absolute value of a *z*-score:

- $|z| \le 2.0$  is acceptable;
- 2.0 < |z| < 3.0 is questionable; and
- $|z| \ge 3.0$  is unacceptable.

### 4.7 E<sub>n</sub>-Score

The  $E_n$ -score is complementary to the z-score in assessment of laboratory performance. The  $E_n$ -score includes uncertainty and is calculated according to Equation 3.

$$E_n = \frac{(\chi - X)}{\sqrt{U_{\chi}^2 + U_X^2}}$$

Equation 3

where:

 $E_n$  is  $E_n$ -score

 $\chi$  is a participant's result

X is the assigned value

 $U_{\chi}$  is the expanded uncertainty of the participant's result

 $U_X$  is the expanded uncertainty of the assigned value

For the absolute value of an  $E_n$ -score:

- $|E_n| \le 1.0$  is acceptable; and
- $|E_n| > 1.0$  is unacceptable.

### 4.8 Traceability and Measurement Uncertainty

Laboratories accredited to ISO/IEC 17025 must establish and demonstrate the traceability and measurement uncertainty associated with their test results.<sup>7</sup>

Guidelines for quantifying uncertainty in analytical measurement are described in the Eurachem/CITAC Guide.<sup>8</sup>

### 5 TABLES AND FIGURES

Table 5

## Sample Details


Sample No.	S1
Matrix	Powder
Analyte	Cocaine
Unit	% base (m/m)

### **Participant Results**


Lab. Code	Result	Uncertainty	z	En
1	60.9	2.4	0.61	0.41
2	59.6	0.63	-0.11	-0.15
3	60.10	1	0.17	0.19
4	61.7	9.3	1.06	0.20
5	57.7	NR	-1.17	-1.75
6	59	2.66	-0.45	-0.27
7	57.49	2.10	-1.29	-0.96
8	57.8	2.9	-1.11	-0.64
9	63.2	2	1.90	1.46
10	61.6	9.2	1.00	0.19
11	58.4	1.8	-0.78	-0.65
12	61.4	8.6	0.89	0.18
13	61	3.9	0.67	0.29
14	55.6	2.6	-2.34	-1.47
15	58.7	2.9	-0.61	-0.35
16	63.52	9.76	2.07	0.38
17	NR	NR		
18	59	4.1	-0.45	-0.19
19	49	7.4	-6.02	-1.44
20	62.87	13.83	1.71	0.22
21	58.5	0.9	-0.72	-0.87
22	60.92	3	0.62	0.35
23	56.5	5.6	-1.84	-0.58
24	60.5	2.6	0.39	0.24
25	59.8	8.7	0.00	0.00
26	62	3.2	1.23	0.64
27	60.59	4.85	0.44	0.16
28	63.00	12.60	1.78	0.25
29	55.81	4.14	-2.22	-0.93
30	NR	NR		

## **Statistics**

Assigned Value	59.8	1.2
Robust Average	59.8	1.2
Median	60.0	1.1
Mean	59.5	
N	28	
Max	63.52	
Min	49	
Robust SD	2.6	
Robust CV	4.3%	



z-Scores: S1 - Cocaine



En-Scores: S1 - Cocaine




Figure 2

Table 6

### **Sample Details**


Sample No.	S2
Matrix	Powder
Analyte	Cocaine
Unit	% base (m/m)

### **Participant Results**


Lab. Code	Result	Uncertainty	z	En
1	83	3.3	0.87	0.59
2	81.3	0.77	0.16	0.26
3	81.10	1.30	0.08	0.11
4	85	12.8	1.69	0.32
5	78.6	NR	-0.95	-1.77
6	80.2	3.61	-0.29	-0.18
7	80.83	2.70	-0.03	-0.02
8	78.4	4.0	-1.03	-0.59
9	85.6	4	1.94	1.12
10	82.6	12.4	0.70	0.14
11	78.4	2.2	-1.03	-0.98
12	81.6	11.4	0.29	0.06
13	82	5.3	0.45	0.20
14	78.7	3.4	-0.91	-0.60
15	77.1	3.9	-1.57	-0.92
16	83.78	9.76	1.19	0.29
17	81.2	4.9	0.12	0.06
18	80	5.6	-0.37	-0.16
19	65	9.8	-6.55	-1.61
20	86.55	19.04	2.33	0.30
21	79.4	1.1	-0.62	-0.88
22	80.01	3	-0.37	-0.27
23	73.1	7.3	-3.21	-1.05
24	79.8	3.5	-0.45	-0.29
25	79.9	3.8	-0.41	-0.25
26	83.9	4.4	1.24	0.65
27	80.60	6.45	-0.12	-0.05
28	87.32	17.46	2.65	0.37
29	79.98	5.93	-0.38	-0.15
30	81.7	5.0	0.33	0.15

### **Statistics**

80.9	1.3	
80.9	1.3	
80.7	1.1	
80.6		
30		
87.32		
65		
2.8		
3.5%		
	80.9 80.7 80.6 30 87.32 65 2.8	80.9 1.3 80.7 1.1 80.6 30 87.32 65 2.8



z-Scores: S2 - Cocaine



En-Scores: S2 - Cocaine




Figure 3

Table 7

### **Sample Details**


Sample No.	S3
Matrix	Powder
Analyte	Cocaine
Unit	% base (m/m)

### **Participant Results**


Lab. Code	Result	Uncertainty	z	En
1	15.1	1.2	2.36	0.79
2	15.2	0.11	2.60	2.65
3	14	0.22	-0.24	-0.22
4	14.6	2.2	1.18	0.22
5	14.5	NR	0.95	1.00
6	14.1	0.63	0.00	0.00
7	13.10	1.20	-2.36	-0.79
8	13.5	0.7	-1.42	-0.74
9	15	1	2.13	0.84
10	14.8	2.2	1.65	0.31
11	12.5	1.3	-3.78	-1.18
12	14.5	2.0	0.95	0.20
13	14	0.9	-0.24	-0.10
14	13.1	0.6	-2.36	-1.39
15	11.3	0.6	-6.62	-3.88
16	14.63	9.76	1.25	0.05
17	14.9	0.9	1.89	0.81
18	15	1.1	2.13	0.77
19	11	1.7	-7.33	-1.78
20	14.28	3.14	0.43	0.06
21	14.2	0.4	0.24	0.18
22	13.81	3	-0.69	-0.10
23	13.4	3	-1.65	-0.23
24	14.7	0.6	1.42	0.83
25	15.1	2.2	2.36	0.45
26	13.5	1.6	-1.42	-0.36
27	13.88	3.00	-0.52	-0.07
28	14.13	2.83	0.07	0.01
29	13.52	1	-1.37	-0.54
30	14.5	0.9	0.95	0.41

### **Statistics**

Assigned Value	14.1	0.4		
Robust Average	14.1	0.4		
Median	14.2	0.4		
Mean	14.0			
N	30			
Max	15.2			
Min	11			
Robust SD	0.83			
Robust CV	5.9%			



z-Scores: S3 - Cocaine



En-Scores: \$3 - Cocaine




Figure 4

Table 8 Participants' Identification of Cutting Agents\*

Lab Cada	Cutting Agents		
Lab. Code	S1	S2	<b>S</b> 3
Preparation	4-Acetamidophenol (paracetamol)	-	Glucose
1	Acetaminophen	-	-
2	Paracetamol	no cutting agent	Glucose/Glucodin
3	Paracetamol	N/A	N/A
4	Acetaminophen	/	Dextrose
5	Acetaminophen: 32.7 %		
6	Paracetamol		Glucose
7	paracetamol		
8	Paracetamol	-	Glucose
9	paracetamol		
10			
11	Paracetamol		
12	Paracetamol		
13	paracetamol		sugar (dextrose)
14	Paracetamol		
15			
16	Paracetamol	None	Glucose
17	-	-	-
18	paracetamol	N/A	N/A
19	paracetamol	none	none
20	acetaminophen	/	/
21	Acetaminophen	N/A	N/A
22	Paracetamol		
23	Paracetamol	insufficient sample	Glucose
24	Paracetamol		glucose
25	Paracetamol	-	Glucose
26	Paracetamol		
27	paracetamol		dextrose
28	Paracetamol	None	Sucralose
29	Paracetamol	none detected	Glucose
30	-	-	-

<sup>\*</sup> Some responses may have been modified so that the participant cannot be identified.

### 6 DISCUSSION OF RESULTS

### 6.1 Assigned Value

The robust averages and associated expanded uncertainties were calculated using the procedure described in ISO 13528.<sup>5</sup> The assigned values for all scored analytes were the robust averages of participants' results, after results less than 50% and greater than 150% of the robust average had been removed.<sup>3,4</sup> The calculation of the expanded uncertainty for a robust average is presented in Appendix 1, using Sample S1 as an example.

**Traceability**: The consensus of participants' results is not traceable to any external reference, so although expressed in SI units, metrological traceability has not been established.

### 6.2 Measurement Uncertainty Reported by Participants

Participants were asked to report an estimate of the expanded MU associated with their results and the basis of this uncertainty estimate (Table 3). Two participants reported using the NATA GAG Estimating and Reporting MU as their guide; NATA no longer publishes this document.<sup>9</sup>

It is a requirement of ISO/IEC 17025 that laboratories have procedures to estimate the uncertainty of chemical measurements and to report this uncertainty in specific circumstances, including when the client's instruction so requires.<sup>7</sup>

Of 88 numeric results, 85 (97%) were reported with an associated expanded MU. Laboratory 5 did not report any uncertainties; this laboratory was not accredited.

The magnitude of reported uncertainties was within the range 0.7% to 67% relative. In general, an expanded uncertainty of less than 3% may be unrealistically small for the routine measurement of illicit drugs, while over 10% may be too large and not fit for purpose. Of the 85 MUs, 47 (55%) were between 3% and 10% relative to the result, ten were less than 3% and 28 were greater than 10%.

Laboratories **16** and **22** reported the same uncertainty across all three samples. Participants were requested to report their uncertainties in units of % base (m/m), however these participants may have reported their uncertainties as relative uncertainties.

Participants were also requested to report the coverage factor associated with their uncertainties (Table 3). Fourteen participants reported a coverage factor of k=2, three participants reported a coverage factor of k=3, one participant reported a coverage factor of k=1 and one participant reported a coverage factor of k=0.95.

Uncertainties associated with results returning an acceptable z-score but an unacceptable  $E_n$ -score may have been underestimated.

In some cases, the results were reported with an inappropriate number of significant figures. Including too many significant figures may inaccurately reflect the precision of measurements. The recommended format is to write the uncertainty to no more than two significant figures, and then to write the result with the corresponding number of decimal places. For example, instead of  $63.52 \pm 9.76\%$  base (m/m), it is better to report  $63.5 \pm 9.8\%$  base (m/m).

### 6.3 z-Score

A target SD equivalent to 3% PCV was used to calculate *z*-scores. The CVs predicted by the Thompson-Horwitz equation,<sup>6</sup> between-laboratory CVs (as robust CV), and target SDs (as PCV) obtained in this study are presented in Table 9.

Table 9 Comparison of Thompson-Horwitz CVs, Between-Laboratory CVs and Target SDs

Sample	Analyte	Assigned Value (% base (m/m))	Thompson-Horwitz CV <sup>a</sup> (%)	Between-Laboratory CV <sup>b</sup> (%)	Target SD (as PCV) (%)
S1	Cocaine	59.8	1.3	4.3	3
S2	Cocaine	80.9	1.1	3.5	3
S3	Cocaine	14.1	2.7	5.9	3


<sup>&</sup>lt;sup>a</sup> Calculated from the assigned value.

Of 88 results for which z-scores were calculated, 70 (80%) returned a z-score of  $|z| \le 2.0$ , indicating an acceptable performance.

Thirteen participants received acceptable z-scores across all three samples: 3, 4, 5, 6, 8, 10, 12, 13, 21, 22, 24, 26 and 27. Laboratories 17 and 30 reported results for two samples, and received acceptable z-scores across both samples.

Fifteen participants returned at least one questionable or unacceptable *z*-score. Laboratory **19** returned unacceptable *z*-scores for all three samples, with all results being lower than the assigned value (negative bias); this participant should check their methodology for the cause of this bias.

The dispersal of participants' z-scores is presented graphically by laboratory in Figure 5.



### 6.4 E<sub>n</sub>-Score

 $E_n$ -Scores can be interpreted in conjunction with *z*-scores, as an unacceptable  $E_n$ -score can be caused by an inappropriate measurement, or uncertainty, or both. If a participant did not report an uncertainty with a result, an expanded uncertainty of zero (0) was used to calculate the  $E_n$ -score.


Of 88 results for which  $E_n$ -scores were calculated, 75 (85%) returned an acceptable  $E_n$ -score of  $|E_n| \le 1.0$ , indicating agreement of the participant's result with the assigned value within their respective expanded uncertainties.

<sup>&</sup>lt;sup>b</sup> Robust between-laboratory CV with outliers removed, if applicable.

Twenty participants received acceptable  $E_n$ -scores across all three samples: 1, 3, 4, 6, 7, 8, 10, 12, 13, 16, 18, 20, 21, 22, 24, 25, 26, 27, 28 and 29. Laboratories 17 and 30 reported results for two samples, and received acceptable  $E_n$ -scores across both samples.

Eight participants returned at least one unacceptable  $E_n$ -score. Laboratory 19 returned unacceptable  $E_n$ -scores for all three samples.

The dispersal of participants'  $E_n$ -scores is presented graphically by laboratory in Figure 6.



### 6.5 Identification of Cutting Agent

The test samples were prepared using seizures of cocaine hydrochloride supplied by the Australian Federal Police. The study coordinator added paracetamol to Sample S1, glucose to Sample S3, and no cutting agents were added to Sample S2.

Twenty-six participants (87%) reported on the identity of the cutting agent(s) in at least one sample (Table 8).

Laboratories 2, 4, 6, 8, 13, 16, 23, 24, 25, 27 and 29 correctly identified all cutting agents in the samples.

A higher proportion of participants were able to identify paracetamol as compared to glucose; all 26 participants who reported on the identity of cutting agents correctly identified paracetamol in Sample S1, as compared to 11 participants who correctly identified glucose in Sample S3. Laboratory 28 incorrectly reported sucralose as the cutting agent in Sample S3.

### 6.6 Participants' Analytical Methods

Participants were requested to analyse the samples using their normal test methods and to report a single result for each sample as they would normally report to a client. Results reported in this way reflect the true variability of results reported to laboratory clients. The method descriptions provided by participants are presented in Table 1, and a summary of accreditation status, methods and reference standards used is presented in Table 10.

Table 10 Summary of Participants' Analyses

		Lab. Code
Accreditation	Yes to ISO/IEC 17025	1, 2, 3, 6, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30
	Not Accredited / Not Reported	4, 5, 7, 9, 15, 27
	< 20	1, 2, 3, 6, 8, 9, 15, 27, 28
Average	20 – 30	4, 7, 10, 13, 14, 16, 17, 18, 20, 22, 23, 26, 29, 30
Sample Mass Used per	31 – 50	5, 12, 19
Analysis (mg)	51 – 100	11, 21, 24
	> 100	25
	Yes	1, 3, 7, 10, 12, 13, 14, 15, 20, 22, 23, 25, 26, 28
Conversion to Base?	No	2, 5, 6, 8, 9, 11, 16, 17, 18, 21, 24, 27, 29, 30
Buse.	Not Reported	4, 19
	HPLC-DAD	3, 4, 9, 11, 18, 23, 25 (S2), 27, 28, 29
	HPLC-UV/Vis	10
Instrument	UPLC-DAD	5, 7, 14, 15, 17, 30
Used for	UPLC-MS/MS	19
Quantification	GC-FID	1, 8, 12, 13, 16, 21, 22, 24, 25 (S1, S3), 26
	GC-MS	20
	QNMR	2, 6
	Acetonitrile	10, 24
	Acetonitrile/Water	4, 14, 15, 27, 28
	Acetonitrile/Water/Acid	3, 29
G 1	Acetonitrile/Methanol(/Water)	7, 19
Solvent	Chloroform	20, 25 (S1, S3)
	Ethanol	5, 8, 13, 21, 26
	Methanol	1, 9, 11, 12, 16, 17, 18, 22, 23, 30
	Other	2, 6, 25 (S2)
	NMI Australia	5, 6, 7, 8, 14, 21, 23, 24
Sources of	Lipomed	1, 4, 10, 11, 13, 15, 17, 18, 20, 27, 28, 30
Calibration	LGC	16, 29
Standard	Other	2, 3, 12, 19, 22, 25, 26
	Not Reported	9

Plots of the *z*-score versus various methodology parameters are presented in Figures 7 to 11. Where charts refer to n = x, this corresponds to *x* number of participants using that methodology.

One participant used UPLC-MS/MS for their measurement; this participant returned low unacceptable results for all samples.




Figure 9 z-Score vs Extraction Solvent




Figure 10 z-Score vs Measurement Instrument




Figure 11 z-Score vs Source of Calibration Standard

### 6.7 Comparison of Results and Date of Analysis

As there were significant delays with sample delivery to some participants, the samples were analysed by participants over the course of approximately five months. No trend was found between when the samples were analysed and the results obtained (Figure 12).




Figure 12 z-Score vs Sample Analysis Date

### 6.8 Comparison with Previous Cocaine PT Studies

To enable direct comparison with previous Cocaine PT studies, the target SD used to calculate *z*-scores has been kept constant at 3% PCV.

A summary of the acceptable performance, presented as a percentage of the total number of scores, obtained by participants from 2014 to 2023 (last 10 studies) are presented in Figure 13. The average proportion of acceptable z-scores and  $E_n$ -scores over this period is 83% and 86% respectively.




Figure 13 Summary of Participants' Performance in Cocaine PT Studies

Several participants have consistently participated in NMI Cocaine PT studies, and individual performance history reports are emailed to each participant at the end of the study. The consideration of *z*-scores for an analyte over time provides much more useful information than a single *z*-score. Over time, laboratories should expect at least 95% of their scores to lie within the range  $|z| \le 2.0$ . Scores in the range 2.0 < |z| < 3.0 can occasionally occur, however, these should be interpreted in conjunction with the other scores obtained by that laboratory. For example, a trend of *z*-scores on one side of the zero line is an indication of method or laboratory bias.

A comparison of all results from Australian and international laboratories in NMI Cocaine PT studies over the last ten years is presented in Figure 14. Overall both groups have performed similarly, with both achieving 83% acceptable *z*-scores over this period.




Figure 14 Comparison of Australian and International Laboratories in NMI Cocaine PT Studies

For those laboratories consistently participating in NMI Cocaine PT studies, a summary of individual laboratory's performances over the last ten studies is presented in Figures 15 and 16 for Australian and international laboratories respectively. One Australian and two international laboratories have achieved acceptable *z*-scores across all samples in all NMI Cocaine PT studies participated in over this period.




Figure 15 Summary of Australian Participants' z-Scores in NMI Cocaine PT Studies




Figure 16 Summary of International Participants' z-Scores in NMI Cocaine PT Studies

### 7 REFERENCES

Please note that for all undated references, the latest edition of the referenced document (including any amendments) applies.

- [1] ISO/IEC 17043:2010, Conformity assessment General requirements for proficiency testing.
- [2] NMI, 2024, *Study Protocol for Proficiency Testing*, viewed May 2024, <a href="https://www.industry.gov.au/sites/default/files/2020-10/cpt\_study\_protocol.pdf">https://www.industry.gov.au/sites/default/files/2020-10/cpt\_study\_protocol.pdf</a>
- [3] NMI, 2024, *Chemical Proficiency Testing Statistical Manual*, viewed May 2024, <a href="https://www.industry.gov.au/sites/default/files/2019-07/cpt\_statistical\_manual.pdf">https://www.industry.gov.au/sites/default/files/2019-07/cpt\_statistical\_manual.pdf</a>
- [4] Thompson, M., Ellison, S.L.R. and Wood, R., 2006, 'The International Harmonized Protocol for the Proficiency Testing of Analytical Chemistry Laboratories', *Pure Appl. Chem.*, vol. 78, pp. 145-196.
- [5] ISO 13528, Statistical methods for use in proficiency testing by interlaboratory comparison.
- [6] Thompson, M., 2000, 'Recent trends in inter-laboratory precision at ppb and sub-ppb concentrations in relation to fitness for purpose criteria in proficiency testing', *Analyst*, vol. 125, pp. 385-386.
- [7] ISO/IEC 17025, General requirements for the competence of testing and calibration laboratories.
- [8] Eurachem/CITAC Guide CG 4, QUAM:2012.P1, *Quantifying Uncertainty in Analytical Measurement*, 3<sup>rd</sup> Edition, viewed May 2024, <a href="http://eurachem.org/images/stories/guides/pdf/quam2012\_P1.pdf">http://eurachem.org/images/stories/guides/pdf/quam2012\_P1.pdf</a>>
- [9] NATA, 2020, *Update to Measurement Uncertainty resources*, viewed May 2024, <a href="https://nata.com.au/news/update-to-measurement-uncertainty-resources/">https://nata.com.au/news/update-to-measurement-uncertainty-resources/</a>

# APPENDIX 1 ROBUST AVERAGE AND ASSOCIATED UNCERTAINTY, z-SCORE AND E<sub>n</sub>-SCORE CALCULATIONS

### A1.1 Robust Average and Associated Uncertainty

Robust averages were calculated using the procedure described in ISO 13528.<sup>5</sup> The associated uncertainties were estimated as according to Equation 4.

$$u_{rob\ av} = 1.25 \times \frac{S_{rob\ av}}{\sqrt{p}}$$
 Equation 4

where:

 $u_{rob \ av}$  is the standard uncertainty of the robust average

 $S_{rob \ av}$  is the standard deviation of the robust average

p is the number of results

The expanded uncertainty ( $U_{rob\ average}$ ) is the standard uncertainty multiplied by a coverage factor of 2 at approximately 95% confidence level.

A worked example for Sample S1 is set out below in Table 11.

Table 11 Uncertainty of Sample S1 Robust Average

No. results (p)	28
Robust average	59.8% base (m/m)
$S_{rob\;average}$	2.6% base (m/m)
Urob average	0.6% base (m/m)
k	2
$U_{rob\;average}$	1.2% base (m/m)

Therefore, the robust average of Sample S1 is  $59.8 \pm 1.2\%$  base (m/m).

### A1.2 z-Score and E<sub>n</sub>-Score Calculations

For each participant's result, a z-score and  $E_n$ -score are calculated according to Equations 2 and 3 respectively (Section 4).

A worked example is set out below in Table 12.

Table 12 z-Score and E<sub>n</sub>-Score Calculation for Sample S1 Result Reported by Laboratory 1

Participant Result (% base (m/m))	Assigned Value (% base (m/m))	Target SD	z-Score	$E_n$ -Score
$60.9 \pm 2.4$	$59.8 \pm 1.2$	3% as PCV, or: 0.03 × 59.8 = 1.794% base (m/m)	$z = \frac{60.9 - 59.8}{1.794}$ $= 0.61$	$E_n = \frac{60.9 - 59.8}{\sqrt{2.4^2 + 1.2^2}}$ $= 0.41$

### **APPENDIX 2 ACRONYMS AND ABBREVIATIONS**

CITAC Cooperation on International Traceability in Analytical Chemistry

CRM Certified Reference Material
CV Coefficient of Variation
DAD Diode Array Detection
EA European Accreditation
FID Flame Ionisation Detection

GAG General Accreditation Guidance (NATA)

GC Gas Chromatography

GUM Guide to the expression of Uncertainty in Measurement

HPLC High Performance Liquid Chromatography
IEC International Electrotechnical Commission
ISO International Organization for Standardization

k Coverage Factor

Max Maximum

Md Median

Min Minimum

MS Mass Spectrometry

MS/MS Tandem Mass Spectrometry
MU Measurement Uncertainty
N Number of numeric results

NATA National Association of Testing Authorities, Australia

NMI National Measurement Institute, Australia

NMR Nuclear Magnetic Resonance

NR Not Reported

PCV Performance Coefficient of Variation

PDA Photodiode Array
PT Proficiency Testing
QNMR Quantitative NMR
RA Robust Average
RM Reference Material
SD Standard Deviation

SI International System of Units

SS Spiked Samples

UPLC Ultra Performance Liquid Chromatography

UV/Vis Ultraviolet/Visible detection

### **END OF REPORT**